Objective To investigate the clinical characteristics and treatment of gastric stromal tumors(GST). Methods The clinical data of patients with proved pathologically gastric stromal tumors admitted from January 2010 to January 2012 were analyzed retrospectively. Results The tumors originated from gastric antrum（n=15）, gastric corpus(n=11),and gastic fundus(n=8), separately.The clinical manifestations found in patients with GST included abdominal discomfort or pain(n=11), abdominal mass(n=14), gastrointestinal bleeding or melena(n=5),and 4 cases were found in physical examination or other surgery (n=4).All the GSTs in this group underwent operation and pathological examination . Immunohistochemical determination revealed that the positive rates of CD117 and CD34 were 94.1% and 73.5% respectively. 32 cases were followed up and 4 cases of recurrent GST received imatinib mesylate therapy. Conclusions The diagnosis of GST should be confirmed by postoperative pathological and immunohistochemical examination Surgery is the main therapy and appropriate targeted therapy improves the survival.
Key words
gastric stromal tumor /
diagnosis /
surgery
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］Mawr M T, Clark H BGastric stromal tumors：reappraisal of histogenesis［J］.Am J Surg Pathol,1983,7(6):507-519.
［2］Miettinen M, Sobin L H, Lasota JGastrointestinal stromal tumors of the stomach:a clinicopathologic,immunohisto chemical,and molecular genetic study of 1765 cases with long term follow up［J］.Am J Surg Pathol, 2005, 29(1):52-68.
［3］沈镭, 刘之中, 成之铮胃肠间质瘤的概念和诊治方法的演变［J］.国外医学消化系统分册，2005，25(3): 160-162
［4］Cichoz-Lach H, Kasztelan-Szczerbinska B, Slomka MGastrointestinal stromal tumors: epidemiology,clinical picture,diagnosis,prognosis and treatment ［J］.Pol Arch Med Wewn, 2008, 118(4): 216-221.
［5］Miettinen M，Sobin L H，Sarlomo- Rikala M． Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117( KIT )［J］．Mod Pathol，2000，13(10): 1134-1142．
［6］Fletcher C D，Berman J J，Corless C， et al.Diagnosis of gastrointestinal stromal tumors: a consensus approach［J］, Hum Pathol, 2002, 33(5): 459-465．
［7］侯英勇，王坚, 朱雄增，等．胃肠道间质瘤76 例的临床病理及免疫组织化学特征［J］．中华病理学杂志，2002，31( 1): 20-25．
［8］Fletcher C D, Berman J J, Corless C, et al.Diagnosis of gastrointestinal stromal tumors: a consensus approach ［J］.Int J Surg Pathol,2002,10(2):81-89.
［9］秦新裕，刘凤林．胃肠道间质瘤的研究进展与展望［J］．中华普通外科杂志，2007，22( 8) : 561-563．
［10］Bai J, Wang Y, Guo H, et al.Endoscopic resection of small gastrointestinal stromal tumors［J］.Dig Dis Sci, 2010, 55: 1950-1954.
［11］Samiian L, Weaver M, Velanovich VEvaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up［J］.Am Surg, 2004, 70(3): 187-191.
［12］Kitamura YGastrointestinal stromal tumors: past, present and future［J］.J Gastroenterol, 2008, 43(7): 499-508.
［13］Dematteo R P, Ballman K V, Antonescu C R, et al.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumors: a randomised, double-blind, placebo-controlled trial［J］. Lancet, 2009, 373(9669): 1097-1104.
PDF(445 KB)
